Xenon Pharmaceuticals to present new long-term data for Azetukalner in focal onset seizures at AAN 2025
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of… read more.
